医学
队列
内科学
造血干细胞移植
移植
疾病
免疫学
队列研究
病毒
养生
肿瘤科
儿科
化疗
天冬酰胺酶
病毒性疾病
噬血细胞性淋巴组织细胞增多症
存活率
生存分析
病毒载量
血液学
前瞻性队列研究
淋巴瘤
作者
Qing Zhang,Yunze Zhao,Dong Wang,Hong‐Hao Ma,Lei Cui,Wei‐Jing Li,Chan‐Juan Wang,Zhigang Li,Rui Zhang
摘要
Chronic active Epstein-Barr virus disease (CAEBV), an Epstein-Barr virus (EBV)+ T/Natural Killer (NK)-cell lymphoproliferative disorder, remains critically undefined in treatment and prognostic stratification due to its rarity. We analysed 149 paediatric systemic CAEBV patients, of whom 134 received LDEP (liposomal doxorubicin, etoposide, pegylated asparaginase and methylprednisolone) chemotherapy as a bridge to haematopoietic stem cell transplantation (HSCT). Diagnostic delay was common (median 6.0 months), with 41.6% presenting atypically with localized symptoms at onset. Haemophagocytic lymphohistiocytosis developed in 50.3%. EBV infection involved pan-lymphoid lineages in 85.2%, with NK-cell predominance (44.3%) enriched in the hydroa vacciniforme/severe mosquito bite allergy subtype. LDEP induced favourable response in 59.0%, significantly improving HSCT rates (98.7% vs. 69.1%). Overall, 127 patients (85.2%) underwent HSCT, with 3-year post-transplant survival of 84.5% ± 3.5%. Inferior post-HSCT survival was independently associated with active disease at transplantation (hazard ratio [HR] = 6.17, p < 0.001) and also linked to longer chemotherapy-to-HSCT interval (>3.5 months) and poor LDEP response. Non-transplanted patient had 90.9% mortality. The entire cohort had a 3-year overall survival of 72.6% from diagnosis, with poor LDEP response, hepatic dysfunction and leucopenia as independent risk factors. This large paediatric cohort defines the clinical spectrum of CAEBV, establishes LDEP as an effective bridging regimen to HSCT-particularly in early-stage disease-and highlights the need for early disease activity control and timely transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI